Acorda adds to PD portfolio with Biotie takeout
Acorda Therapeutics Inc. (NASDAQ:ACOR) will acquire Biotie Therapies Corp. (HSE:BTH1V; NASDAQ:BITI) for about $363 million in cash. The deal gives Acorda two clinical stage programs for Parkinson's disease, including oral selective adenosine A2A receptor ( ADORA2A) antagonist tozadenant